Landmark Alzheimer's Prevention Trial

May 17th, 2012

Genentech, the Banner Alzheimer's Institute and the National Institutes of Health partner for first-ever study of cognitively healthy individuals

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health have collaborated on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.

The landmark trial was the first to assess the potential of a medicine to stop Alzheimer's before it starts and is the cornerstone of a new international collaborative, the Alzheimer's Prevention Initiative (API), formed to accelerate the evaluation of promising but unproven prevention therapies. The study took place in Medellin, Colombia and involved about 250 participants from local families that can be traced to a common descendant. The participants share a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45.

The study involved crenezumab, a humanized monoclonal antibody, which is designed to bind to beta-amyloid , the main constituent of amyloid plaque in the brains of patients with Alzheimer's disease. Beta-amyloidis proposed to be causative in the development of the disease.

Why this trial is historic

  • The trial studied patients before they showed any symptoms of cognitive decline.
  • There is significant unmet medical need within this unique patient population.

Significance and description of the trial

  • A shift in the research paradigm icon-down-arrow.png
  • Unmet medical need in a unique patient population Down arrow
  • About the amyloid hypothesis Down arrow
  • Who's participating in the study Down arrow


Related resources

People who are interested in supporting Alzheimer's prevention initiatives in the United States are encouraged to join the API's Alzheimer's Prevention Registry. The registry is a community of people interested in the possibility of participating in Alzheimer's prevention studies, now or in the future.

Richard Scheller discusses the trial

Watch the interview series with Genentech's Executive Vice President of Research and Early Development,Richard Scheller.

About Crenezumab

Follow this story